Original Article
Clinical efficacy of complex packing estradiol tablets/estradiol and dydrogesterone tablets and tibolone in postmenopausal hormone therapy
Xiaoying Zhang, Fengxia Gao, Weimin Li, Chunmei Piao, Kefang Wang
Published 2017-04-08
Cite as Chin Med, 2017, 12(4): 598-602. DOI: 10.3760/cma.j.issn.1673-4777.2017.04.029
Abstract
ObjectiveTo explore clinical efficacy of postmenopausal hormone therapy(MHT) with complex packing estradiol tablets/estradiol and dydrogesterone tablets(femonston) and tibolone.
MethodsEighty menopausal female patients with MHT from March to December 2015 in Beijing Pinggu Hospital were randomly divided into femonston group and tibolone group, with 40 cases in each group. The femonston group took femonston sequentially, 1 pill/d; the tibolone group took tibolone 0.5 pill/d; both groups were treated for 6 months. General data, Kupperman score, blood lipid, blood glucose, alanine aminotransferase(ALT), creatinine, body mass index(BMI) and adverse reactions were analyzed.
ResultsKupperman scores after 1, 3, 6 months of treatment in both groups were significantly lower than those before treatment[tibolone group: (10.8±4.0), (5.6±2.4), (4.5±1.8)scores vs (22.8±3.1)scores; femonston group: (10.7±4.5), (5.2±1.3), (5.0±1.3) scores vs (22.0±3.6)scores](P<0.05); there were no significant differences between groups(P>0.05). Levels of cholesterol, triacylglycerol, low density lipoprotein cholesterol(LDL-C), ALT, blood glucose, creatinine and BMI after 6 months of treatment showed no significant differences compared to those before treatment in both groups[tibolone group: (4.7±1.0)mmol/L vs (4.5±0.9)mmol/L, (1.8±0.9)mmol/L vs (1.7±0.9)mmol/L, (2.7±0.6)mmol/L vs (2.5±0.6)mmol/L, (15±4)U/L vs (15±5)U/L, (5.2±0.3)mmol/L vs (5.1±0.4) mmol/L, (61±5)μmol/L vs (58±10)μmol/L, (23.2±1.6)kg/m2 vs (23.2±1.6)kg/m2; femonston group: (4.9±0.5)mmol/L vs (4.8±0.6)mmol/L, (1.6±0.6)mmol/L vs (1.6±0.4)mmol/L, (2.6±0.5)mmol/L vs (2.7±0.6)mmol/L, (14±5)U/L vs (14±4)U/L, (5.0±0.5)mmol/L vs (5.0±0.5)mmol/L, (59±7)μmol/L vs (61±8)μmol/L, (22.8±2.1)kg/m2 vs (22.7±2.3)kg/m2](P>0.05). Levels of high density lipoprotein cholesterol(HDL-C) after 6 months of trearment were significantly higher than those before treatment in both groups[tibolone group: (1.63±0.41)mmol/L vs (1.35±0.22)mmol/L; femonston group: (1.62±0.26)mmol/L vs (1.44±0.26)mmol/L](P<0.05). There were no significant differences of cholesterol, triacylglycerol, HDL-C, LDL-C, ALT, blood glucose, creatinine and BMI between groups(P>0.05). Main adverse reactions were vaginal bleeding and breast swelling pain; the incidence of adverse reactions between tibolone group and femonston group was not significant[30.0%(12/40) vs 15.0%(6/40)](P>0.05).
ConclusionFemonston and tibolone can alleviate climacteric symptoms and increase the level of HDL-C in patient with MHT.
Key words:
Menopausal hormone therapy; Complex packing estradiol tablets/estradiol and dydrogesterone tablets; Tibolone
Contributor Information
Xiaoying Zhang
Department of Gynecology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
Fengxia Gao
Department of Gynecology, Beijing Pinggu Hospital of Beijing Friendship Hospital, Capital Medical University, Beijing 101200, China
Weimin Li
Department of Gynecology, Beijing Pinggu Hospital of Beijing Friendship Hospital, Capital Medical University, Beijing 101200, China
Chunmei Piao
Department of Gynecology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
Kefang Wang
Department of Gynecology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
